Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA for urinary incontinence in MS
NCT01600716Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2012
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of onabotulinumtoxinA in neurogenic detrusor overactivity (NDO), urinary incontinence (UI), sponsored by Allergan. Started Jun 2012; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
neurogenic detrusor overactivity (NDO)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT01600716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01600716.